ArticleGenes2025
A Study on the Diagnostic and Prognostic Value of Extrachromosomal Circular DNA in Breast Cancer.
Article in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extrachromosomal DNA in Solid Tumors-Landscape, Immune Effects, and Resistance to Targeted Therapy.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesTo investigate the clinical diagnostic and prognostic value of extrachromosomal circular DNA (eccDNA) in breast cancer, eccDNA profiles were constructed for 81 breast cancer tumor tissues and 33 adjacent non-tumor tissues.
methodsThe distribution characteristics of eccDNA across functional genomic elements and repetitive sequences were systematically analyzed. Furthermore, a diagnostic model for differentiating malignant and normal breast tissues, as well as a prognostic prediction model, was developed using a random forest algorithm.
resultsEccDNA in breast cancer tissues harbor a higher proportion of functional elements and repetitive sequences, with their annotated genes significantly enriched in tumor- and immune-related pathways. However, no significant differences in eccDNA features were observed across breast cancer subtypes or pathological stages. In the validation cohort, the eccDNA-based diagnostic model achieved an AUC of 0.83, with repetitive elements and enhancer-associated features contributing the most to diagnostic performance. The prognostic model achieved an AUC of 0.78, with repetitive element annotations also showing strong prognostic relevance.
conclusionsThese findings highlight the promising potential of eccDNA in the development of precision diagnostics and prognostic systems for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.